Geet Aggarwal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Geet Aggarwal has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
Dinesh Arora
23 shared publications- Aseem Kumar Tiwari
Department of Transfusion Medicine, Medanta-The Medicity, Gurgaon, Haryana, India
22 shared publications Ravi C Dara
Department of Transfusion Medicine, Manipal Hospital, Jaipur, Rajasthan, India
11 shared publicationsGunjan Bhardwaj
Department of Transfusion Medicine, Medanta-The Medicity, Secor-38, Gurugram, Haryana, India
9 shared publicationsAseem K Tiwari
Department of Transfusion Medicine, Medanta-The Medicity, Gurgaon, Haryana, India
6 shared publicationsVimarsh Raina
Laboratory Services and Transfusion Medicine, Medanta-The Medicity, Sector-38, Gurgaon 122001, India
6 shared publications
Latest Publications
- 23 March 2026
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 34 (5) , 1374-1380
CARMN::NOTCH2 Fusion-Positive Malignant Glomus Tumor of the Liver: A Rare Tumor With Review of Literature
Glomus tumors are rare mesenchymal neoplasms that commonly occur in distal extremities. Primary hepatic involvement is exceedingly uncommon, with only ten tumors reported to date, most of which were benign. Malignant hepatic glomus tumors are exceptionally rare, and their molecular features remain poorly characterized. Recent studies have identified recurrent CARMN::NOTCH2 fusions as potential defining alterations in malignant glomus tumors. We report a 57-year-old man presenting with epigastric pain, reflux, and diarrhea. Imaging revealed a 10 cm left hepatic lobe mass, initially concerning hepatocellular carcinoma, and an incidental subcutaneous hip lesion. Biopsy of the latter confirmed low-grade fibromyxoid sarcoma, considered unrelated. Extended left hepatectomy revealed a multinodular, hemorrhagic hepatic tumor. Histology demonstrated epithelioid to spindle cells with moderate-to-marked atypia, prominent nucleoli, brisk mitotic figures including atypical forms, and focal myxoid stroma. Immunohistochemistry was positive for smooth muscle actin and vimentin, and negative for epithelial, vascular, melanocytic, and gastrointestinal stromal tumor markers. Sarcoma fusion testing identified a CARMN::NOTCH2 fusion, with MDM2 non-amplified and next-generation sequencing showing microsatellite stability and low tumor mutational burden. Based on morphologic, immunohistochemical, and molecular findings, a diagnosis of malignant hepatic glomus tumor was rendered. To our knowledge, this represents only the third reported malignant hepatic glomus tumor with molecular confirmation of CARMN::NOTCH2 fusion. This tumor highlights the diagnostic challenges posed by hepatic glomus tumors, underscores the importance of integrating molecular studies into unusual hepatic neoplasms, and expands the clinicopathologic and molecular spectrum of this exceedingly rare entity.
- 23 March 2026
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 34 (5) , 1374-1380
CARMN::NOTCH2 Fusion-Positive Malignant Glomus Tumor of the Liver: A Rare Tumor With Review of Literature
Glomus tumors are rare mesenchymal neoplasms that commonly occur in distal extremities. Primary hepatic involvement is exceedingly uncommon, with only ten tumors reported to date, most of which were benign. Malignant hepatic glomus tumors are exceptionally rare, and their molecular features remain poorly characterized. Recent studies have identified recurrent CARMN::NOTCH2 fusions as potential defining alterations in malignant glomus tumors. We report a 57-year-old man presenting with epigastric pain, reflux, and diarrhea. Imaging revealed a 10 cm left hepatic lobe mass, initially concerning hepatocellular carcinoma, and an incidental subcutaneous hip lesion. Biopsy of the latter confirmed low-grade fibromyxoid sarcoma, considered unrelated. Extended left hepatectomy revealed a multinodular, hemorrhagic hepatic tumor. Histology demonstrated epithelioid to spindle cells with moderate-to-marked atypia, prominent nucleoli, brisk mitotic figures including atypical forms, and focal myxoid stroma. Immunohistochemistry was positive for smooth muscle actin and vimentin, and negative for epithelial, vascular, melanocytic, and gastrointestinal stromal tumor markers. Sarcoma fusion testing identified a CARMN::NOTCH2 fusion, with MDM2 non-amplified and next-generation sequencing showing microsatellite stability and low tumor mutational burden. Based on morphologic, immunohistochemical, and molecular findings, a diagnosis of malignant hepatic glomus tumor was rendered. To our knowledge, this represents only the third reported malignant hepatic glomus tumor with molecular confirmation of CARMN::NOTCH2 fusion. This tumor highlights the diagnostic challenges posed by hepatic glomus tumors, underscores the importance of integrating molecular studies into unusual hepatic neoplasms, and expands the clinicopathologic and molecular spectrum of this exceedingly rare entity.
- 17 August 2022
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 39 (2) , 300-307
Comparison of Two Different Serological Viral Marker Testing Assays for Screening of Apheresis Donors: Which Assay Provides Optimum Safety for Transfusion?
While whole blood testing has evolved over the years, viral marker testing for plateletpheresis donors is still performed by Rapid Diagnostic Tests (RDT). Aim of this study was to compare diagnostic accuracy of RDT and Chemiluminescence Immunoassay (CLIA) in serological testing for HBsAg, anti-HCV and anti-HIV antibodies. A prospective, analytical study was conducted in the department of Transfusion Medicine at a tertiary healthcare center in India between September 2016 and August 2018. Samples were simultaneously tested by CLIA, RDT and a confirmatory test. Sensitivity, specificity, negative and positive predictive values and mean time taken to report results were calculated. A total of 102 (1.48%) of the 6883 samples were found to be reactive by either or both the assays. A total of 74 (1.08%) samples were HBsAg reactive, 23 (0.33%) were reactive for anti-HCV antibodies and 5 (0.07%) were reactive for anti-HIV I and II antibodies. A combined sero-prevalence of 1.05% (72) was observed; 0.78% (54) for HBsAg, 0.26% (18) for anti-HCV antibodies and none for anti-HIV I and II antibodies. Four (3.85%) reactive samples were missed by RDT and therefore sensitivity of RDT was quite less as compared to CLIA. RDT and CLIA both were found to have a statistically significant shorter turnaround time than confirmatory tests. There is increasing need to develop a safe donor screening strategy for plateletpheresis. CLIA offers an excellent alterative to RDT for viral marker testing in terms of sensitivity.
- 17 August 2022
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 39 (2) , 300-307
Comparison of Two Different Serological Viral Marker Testing Assays for Screening of Apheresis Donors: Which Assay Provides Optimum Safety for Transfusion?
While whole blood testing has evolved over the years, viral marker testing for plateletpheresis donors is still performed by Rapid Diagnostic Tests (RDT). Aim of this study was to compare diagnostic accuracy of RDT and Chemiluminescence Immunoassay (CLIA) in serological testing for HBsAg, anti-HCV and anti-HIV antibodies. A prospective, analytical study was conducted in the department of Transfusion Medicine at a tertiary healthcare center in India between September 2016 and August 2018. Samples were simultaneously tested by CLIA, RDT and a confirmatory test. Sensitivity, specificity, negative and positive predictive values and mean time taken to report results were calculated. A total of 102 (1.48%) of the 6883 samples were found to be reactive by either or both the assays. A total of 74 (1.08%) samples were HBsAg reactive, 23 (0.33%) were reactive for anti-HCV antibodies and 5 (0.07%) were reactive for anti-HIV I and II antibodies. A combined sero-prevalence of 1.05% (72) was observed; 0.78% (54) for HBsAg, 0.26% (18) for anti-HCV antibodies and none for anti-HIV I and II antibodies. Four (3.85%) reactive samples were missed by RDT and therefore sensitivity of RDT was quite less as compared to CLIA. RDT and CLIA both were found to have a statistically significant shorter turnaround time than confirmatory tests. There is increasing need to develop a safe donor screening strategy for plateletpheresis. CLIA offers an excellent alterative to RDT for viral marker testing in terms of sensitivity.
- Open Access
- 1 January 2022
- Published by Jaypee Brothers Medical Publishing in Global Journal of Transfusion Medicine
- Vol. 7 (1) , 65-70
Experiences, Challenges, and Their Mitigation during COVID Convalescent Plasma Donation Management
Background and Objectives: ICMR conducted a multicentric trial “PLACID” that allowed COVID convalescent plasma (CCP) as an experimental drug for the management of moderate COVID-19 disease and the authors' institute was one of the participating centers. The efficacy of CCP in COVID-19 is still debatable. However, unlike therapeutic efficacy, there is not enough literature on issues and challenges faced by health-care institutions in donor recruitment, and the entire vein-to-vein process and approach of CCP transfusion. The authors would like to share their experiences, challenges faced, and their mitigation during the course of donor recruitment, screening, testing, apheresis donation, storage, inventory management, and issue and transfusion of CCP including the regulatory provisions, as their evolution. Methods: This retrospective study was conducted over a period of 7 months at a large tertiary care hospital in north India. Based on ICMR guidelines, the study analyzed the screening process and donation from all consecutive potential CCP donors. The study also identified various issues and challenges faced by the institute and how they were resolved. Results: Prospective donors registered at the blood center were 843. Majority were males (96.6%), first-time CCP donors (93%), age interval 31–45 years (52.2%), who had a history of mild COVID-19 symptoms (86.9%), and were home-quarantined (83.8%). The most common blood group was B positive (50.6%). Only 6.3% of donors were deferred due to the absence of anti-COVID-19 antibodies. Of 843, 705 selected CCP donors donated 1488 CCP units and six donors (0.8%) experienced mild adverse reactions. Challenges faced by authors included donor recruitment, lack of regulatory approval for plasmapheresis, revisions of COVID-specific selection criteria, no “anti-COVID-19 antibody” kit, and CCP inventory management. Conclusion: This study provides real-world comprehensive data on process management of CCP donors and their donations. This understanding of the process, its challenges, and their mitigation could be a template for any possible future pandemic.
- 1 January 2022
- Published by Jaypee Brothers Medical Publishing in Global Journal of Transfusion Medicine
- Vol. 7 (1) , 65-70
Open AccessExperiences, Challenges, and Their Mitigation during COVID Convalescent Plasma Donation Management
Background and Objectives: ICMR conducted a multicentric trial “PLACID” that allowed COVID convalescent plasma (CCP) as an experimental drug for the management of moderate COVID-19 disease and the authors' institute was one of the participating centers. The efficacy of CCP in COVID-19 is still debatable. However, unlike therapeutic efficacy, there is not enough literature on issues and challenges faced by health-care institutions in donor recruitment, and the entire vein-to-vein process and approach of CCP transfusion. The authors would like to share their experiences, challenges faced, and their mitigation during the course of donor recruitment, screening, testing, apheresis donation, storage, inventory management, and issue and transfusion of CCP including the regulatory provisions, as their evolution. Methods: This retrospective study was conducted over a period of 7 months at a large tertiary care hospital in north India. Based on ICMR guidelines, the study analyzed the screening process and donation from all consecutive potential CCP donors. The study also identified various issues and challenges faced by the institute and how they were resolved. Results: Prospective donors registered at the blood center were 843. Majority were males (96.6%), first-time CCP donors (93%), age interval 31–45 years (52.2%), who had a history of mild COVID-19 symptoms (86.9%), and were home-quarantined (83.8%). The most common blood group was B positive (50.6%). Only 6.3% of donors were deferred due to the absence of anti-COVID-19 antibodies. Of 843, 705 selected CCP donors donated 1488 CCP units and six donors (0.8%) experienced mild adverse reactions. Challenges faced by authors included donor recruitment, lack of regulatory approval for plasmapheresis, revisions of COVID-specific selection criteria, no “anti-COVID-19 antibody” kit, and CCP inventory management. Conclusion: This study provides real-world comprehensive data on process management of CCP donors and their donations. This understanding of the process, its challenges, and their mitigation could be a template for any possible future pandemic.
- Open Access
- 10 July 2021
- Published by Wiley in Cancer Reports
- Vol. 4 (6) , e1408
Peripheral blood stem cell mobilization with pegylated granulocyte colony stimulating factor in children
Background and Aim: We report here our experience of using pegylated granulocyte colony stimulating factor (peg‐GCSF) for peripheral blood stem cell (PBSC) mobilization in children.Methods and results: A total of nine children suffering from high‐risk/relapsed solid tumors were mobilized with chemotherapy and peg‐GCSF (100 microgram/kg single dose). Mean age was 7.7 years (range 2–15 years).The mean time from peg‐GCSF administration to PBSC harvest was 9.7 days. Adequate stem cells (median dose 26.9 million/kg) could be harvested in all children by a single apheresis procedure. No major adverse events observed.Conclusion: It is feasible and safe to mobilize PBSC with peg‐GCSF in children with cancer.
- 10 July 2021
- Published by Wiley in Cancer Reports
- Vol. 4 (6) , e1408
Open AccessPeripheral blood stem cell mobilization with pegylated granulocyte colony stimulating factor in children
Background and Aim: We report here our experience of using pegylated granulocyte colony stimulating factor (peg‐GCSF) for peripheral blood stem cell (PBSC) mobilization in children.Methods and results: A total of nine children suffering from high‐risk/relapsed solid tumors were mobilized with chemotherapy and peg‐GCSF (100 microgram/kg single dose). Mean age was 7.7 years (range 2–15 years).The mean time from peg‐GCSF administration to PBSC harvest was 9.7 days. Adequate stem cells (median dose 26.9 million/kg) could be harvested in all children by a single apheresis procedure. No major adverse events observed.Conclusion: It is feasible and safe to mobilize PBSC with peg‐GCSF in children with cancer.
- Open Access
- 1 July 2021
- Published by Medknow in Indian Journal of Transplantation
- Vol. 15 (3) , 279-281
Pretransplant Compatibility Tests in Kidney Transplants
Pre-transplant compatibility work-up has evolved tremendously from conventional CDC only to CDC with more sensitive FCXM testing with bead-based assays (LMX and SAB). Detection of alloantibodies is one of the major objective in work-up algorithm. Conventionally cell-based tests were used, if both are negative, hospital usually proceeds for transplantation. If one of the screening tests (CDC/FCXM) is or both (CDC and FCXM) screening tests are positive, antibody identification is performed on Luminex platform to determine DSA by virtual cross-match. However, cell-based tests have their limitations. Here, we described a case which could have gone unnoticed if HLA bead-based assay was not there and could have triggered AMR (Antibody mediated rejection) as detected antibody (DRB1*07:01; BCM is 16416) was DSA.
- 1 July 2021
- Published by Medknow in Indian Journal of Transplantation
- Vol. 15 (3) , 279-281
Open AccessPretransplant Compatibility Tests in Kidney Transplants
Pre-transplant compatibility work-up has evolved tremendously from conventional CDC only to CDC with more sensitive FCXM testing with bead-based assays (LMX and SAB). Detection of alloantibodies is one of the major objective in work-up algorithm. Conventionally cell-based tests were used, if both are negative, hospital usually proceeds for transplantation. If one of the screening tests (CDC/FCXM) is or both (CDC and FCXM) screening tests are positive, antibody identification is performed on Luminex platform to determine DSA by virtual cross-match. However, cell-based tests have their limitations. Here, we described a case which could have gone unnoticed if HLA bead-based assay was not there and could have triggered AMR (Antibody mediated rejection) as detected antibody (DRB1*07:01; BCM is 16416) was DSA.
- 1 December 2020
- Published by Elsevier in Journal of Immunological Methods
- Vol. 487, 112895
An algorithmic approach to serological work-up of ABO sub-groups which present as ABO discrepancies in resource constraint settings
- 1 December 2020
- Published by Elsevier in Journal of Immunological Methods
- Vol. 487, 112895
An algorithmic approach to serological work-up of ABO sub-groups which present as ABO discrepancies in resource constraint settings
- 1 November 2020
- Published by Elsevier in Journal of Virological Methods
- Vol. 285, 113962
Head-to-head comparison of Enzyme Linked Immunosorbent Assay (ELISA) and Enhanced Chemiluminescence Immunoassay (ECLIA) for the detection of Transfusion Transmitted Disease (TTD) Markers; HIV, HCV and HBV in blood donors, in India
- 1 November 2020
- Published by Elsevier in Journal of Virological Methods
- Vol. 285, 113962
Head-to-head comparison of Enzyme Linked Immunosorbent Assay (ELISA) and Enhanced Chemiluminescence Immunoassay (ECLIA) for the detection of Transfusion Transmitted Disease (TTD) Markers; HIV, HCV and HBV in blood donors, in India
- Open Access
- 1 January 2020
- Published by Medknow in Indian Journal of Pathology and Microbiology
- Vol. 63 (2) , 255-257
Utility of grey zone testing strategy in transfusion transmissible infection testing in blood bank is of limited value!
Several blood banks use grey zone (GZ) phenomenon (defined as samples with optical density within 10% below the cut off in enzyme immuno-assay [EIA]/chemiluminescence immunoassay [CLIA]) to further augment blood safety. There is paucity of data regarding usefulness of GZ sample and its application in Transfusion Transmissible Infection (TTI) screening procedures in blood transfusion services. We looked at our GZ sample results and their confirmatory test results to verify if it adds to blood safety in our set-up? We performed a prospective analytical study on blood donors' samples over two years. All the donors' samples were screened for TTI using CLIA. Samples with signal/cut-off ratio between ≥0.90 and <1.00 were classified under GZ. They were re-tested in duplicate and submitted to confirmatory testing: Neutralization Test for HBsAg, Immunoblot for HCV, and Western blot for HIV. Among the 50,064 blood donors donating the blood during study period, 573 (1.14%) donors were reactive for HBsAg, HCV, and HIV. Forty-seven (0.1%) TTI samples were GZ, but none was “confirmed positive.” The utility of GZ testing seems to be limited. However, this may be continued for sake of “erring on the side of caution” and since this only results in negligible wastage (0.1%) of blood units.
- 1 January 2020
- Published by Medknow in Indian Journal of Pathology and Microbiology
- Vol. 63 (2) , 255-257
Open AccessUtility of grey zone testing strategy in transfusion transmissible infection testing in blood bank is of limited value!
Several blood banks use grey zone (GZ) phenomenon (defined as samples with optical density within 10% below the cut off in enzyme immuno-assay [EIA]/chemiluminescence immunoassay [CLIA]) to further augment blood safety. There is paucity of data regarding usefulness of GZ sample and its application in Transfusion Transmissible Infection (TTI) screening procedures in blood transfusion services. We looked at our GZ sample results and their confirmatory test results to verify if it adds to blood safety in our set-up? We performed a prospective analytical study on blood donors' samples over two years. All the donors' samples were screened for TTI using CLIA. Samples with signal/cut-off ratio between ≥0.90 and <1.00 were classified under GZ. They were re-tested in duplicate and submitted to confirmatory testing: Neutralization Test for HBsAg, Immunoblot for HCV, and Western blot for HIV. Among the 50,064 blood donors donating the blood during study period, 573 (1.14%) donors were reactive for HBsAg, HCV, and HIV. Forty-seven (0.1%) TTI samples were GZ, but none was “confirmed positive.” The utility of GZ testing seems to be limited. However, this may be continued for sake of “erring on the side of caution” and since this only results in negligible wastage (0.1%) of blood units.
- Open Access
- 1 January 2020
- Published by Scientific Scholar in Indian Journal of Nephrology
- Vol. 30 (1) , 55-+
Discordance between Flow-Cytometry Crossmatch and single antigen bead (SAB) assay: An uncommon finding and its resolution
J Indian Prosthodont Soc, Official publication of Indian Prosthodontic Society
- 1 January 2020
- Published by Scientific Scholar in Indian Journal of Nephrology
- Vol. 30 (1) , 55-+
Open AccessDiscordance between Flow-Cytometry Crossmatch and single antigen bead (SAB) assay: An uncommon finding and its resolution
J Indian Prosthodont Soc, Official publication of Indian Prosthodontic Society